Elgemtumab（Cat No.:I041524）is an investigational monoclonal antibody being studied for its potential in cancer treatment. It targets the HER3 receptor, which is often overexpressed in various cancers, including breast, lung, and ovarian cancers. By binding to HER3, elgemtumab aims to inhibit cancer cell signaling pathways that promote tumor growth and survival. It is being evaluated in clinical trials, both as a monotherapy and in combination with other treatments, to improve outcomes for patients with solid tumors. Elgemtumab is part of the growing field of targeted therapies focused on tumor-specific receptors.
